Patients value anticancer therapies that provide durable clinical responses; immune-checkpoint inhibitors can provide such benefit for patients with some advanced-stage malignancies, albeit only for a minority of those treated. Modern oncology value frameworks have set efficacy thresholds in an attempt to assess the clinical benefit of anticancer therapeutics. But, is the benefit of durable cancer control reflected in these thresholds?See it on, via Viruses, Immunology & Bioinformatics from
Cancer immunotherapy and the value of cure
Source: Viral Bioinformatics

Tagged with:

Comments are closed.